2011 多发性骨髓瘤进展CCO_Hematology_2011_MM_Slides_CME幻灯片.pptVIP

MM, multiple myeloma; MTD, maximum tolerated dose; PR, partial response; SD, stable disease; VGPR, very good partial response. ? Amitabha Mazumder, MD: Kumar and colleagues studied the weekly dosing schedule, delivering MLN9708 on Days 1, 8, and 15 of a 28-day cycle, which is similar to the weekly dosing schedule for bortezomib. However, with MLN9708, even heavily pretreated patients are receiving benefits with different and less severe toxicities. ? Kenneth Anderson, MD: We had the opportunity to do some of the preclinical testing on oral MLN9708, and it was well tolerated in our animal mo